Mon Oct 13 03:40:00 UTC 2025: ## Rubicon Research IPO: Overvalued and Risky? Experts Weigh In

**New Delhi:** The Rubicon Research IPO, which opened this week alongside the Canara Robeco IPO, has garnered significant investor attention, particularly due to its Gross Market Premium (GMP). However, experts caution potential investors to look beyond the GMP before committing their funds.

The IPO saw strong retail interest on its second day, with a subscription rate of 2.41 times. The overall subscription rate stood at 0.86 times.

While the initial enthusiasm is evident, brokerage firm Ventura and other analysts advise investors to consider several key factors, including revenue trends, valuation, issue structure, and market capitalization, both pre and post-listing.

**Financial Performance:**

While Rubicon Research has demonstrated growth between FY2023-24 and FY2025-26, the revenue increase between FY2022-23 and FY2023-24 was minimal.

**Valuation Concerns:**

Analysts highlight that Rubicon Research’s Price-to-Earnings (P/E) ratio is higher compared to its peers in the pharmaceutical sector, suggesting the company may be overvalued. This means the stock is potentially being offered at a price higher than its intrinsic value.

**Dependence on US Market & Tariff Risks:**

A significant 98.49% of Rubicon Research’s revenue in FY2024-25 came from the US market. Given the ongoing trade sensitivities between the US and India, experts advise caution due to the potential impact of tariffs on the company’s exports.

**IPO Details:**

* **Shares Offered:** 2,84,02,040
* **Total Value:** ₹1,377.50 Crore
* **Post-Issue Market Cap (estimated):** ₹7954 Crore
* **Price Band:** ₹461 – ₹485 per share
* **Issue Price (expected):** ₹485 per share

**Expert Advice:**

Considering the potential overvaluation and reliance on the US market amid evolving trade relations, financial advisors are urging investors to exercise caution and conduct thorough research before investing in the Rubicon Research IPO.

**(Disclaimer: This news report is for informational purposes only and does not constitute investment advice. The stock market carries inherent risks, and it is recommended to consult with a certified investment advisor before making any investment decisions.)**

Read More